Broad-spectrum Antiviral Inhibits SARS-CoV-2


Disclaimer: This article is a summary of Research article by Sheahan et al, Pre-print published on BioRxiv. This research article at the time of writing this summary has not been peer-reviewed.

SARS-CoV-2 is a zoonotic virus which causes the disease COVID-19 and there are currently no approved therapies. Sheahan et al recently pre-published a paper that states that ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad spectrum antiviral activity against SARS-CoV 2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoV. The researchers also stated that there is an increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.

EIDD-2801, an orally bioavailable NHC-prodrug (b-D-N4-hydroxycytidine-5’-isopropyl ester) was also shown to improve pulmonary function and reduce virus titre in mice infected with SARS-CoV or MERS-CoV. NHC/EIDD-2801 was shown to be potent against multiple coronaviruses and therapeutically effective which highlights its potential as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.

Journal Article: BioRxiv – Sheahan, T.P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

Article by Bonamy Holtak

International Union of Immunological SocietiesUniversity of South AfricaInstitute of Infectious Disease and Molecular MedicineScience Education PrizesElizabeth Glazer Pediatric Aids Foundation